The first monoclonal antibody (mAbs) to treat COVID-19 has joined a short list of U.S. Food and Drug Administration (FDA) approved antivirals.
Roche announced yesterday that the FDA had approved Actemra® (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients receiving systemic corticosteroids and requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
First Monoclonal Antibody to Treat COVID-19 Approved
First Approved Capsid Inhibitor-Based HIV Treatment Option
While the U.S. Food and Drug Administration (FDA) has yet to approve an HIV vaccine candidate, approvals have been granted for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.
Gilead Sciences, Inc. announced today that Sunlenca® (lenacapavir), in combination with other antiretrovirals, has been granted approval by the U.S. FDA for treating HIV-1 infection in HTE adults with MDR HIV-1 infection.
Sunlenca is now the first and only FDA Approved Capsid Inhibitor-Based HIV treatment option.
Children’s Firearm Injuries Up During the Pandemic
Significant increases seen among children who are Black, very young, and with public insurance
Life Expectancy Down to 76.4 Years in 2021
Age-specific deaths rates increased for all age groups 1 year and over; no significant change seen in infant mortality rates